Presentation TCT 2012 If You Want the Truth, Randomize! Presenter: Robert Harrington October 24, 2012
News Daily News ROCKET AF: Stopping Rivaroxaban or Warfarin Equally Harmful in A-fib Patients Caitlin E. Cox April 26, 2012
News Daily News ROCKET AF: Interrumpir la Toma de Rivaroxaban o Warfarina es Igual de Perjudicial en Pacientes con Fibrilación Auricular Caitlin E. Cox April 26, 2012
News Conference News ACC 2012 INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI Jason Kahn March 25, 2012
News Conference News ACC 2012 Color Coding, Checklists Improve Use of Evidence-Based Strategies for ACS L.A. McKeown March 25, 2012
News Daily News Mitral Repair Can Augment Heart Function in CABG Patients Caitlin E. Cox March 04, 2012
News Daily News La Reparación Mitral Puede Aumentar la Función Cardíaca en Pacientes sometidos a CABG Caitlin E. Cox March 04, 2012
Presentation TCT 2012 In Vivo Characterization of Bioresorbable Vascular Scaffold Strut Interfaces Using Optical Coherence Tomography with Gaussian Line Spread Function Analysis Presenter: Alexander Sheehy, Juan Luis Guti?rrez-Chico, Roberto Diletti, James P Oberhauser, Thierry Glauser, Joel Harrington, Mary Beth Kossuth, Richard J Rapoza, Yoshinobu Onuma, Patrick W. Serruys January 03, 2012
News Industry News Abbott Receives U.S. FDA Approval for Next-Generation XIENCE PRIME™ Drug Eluting Stent November 01, 2011
News Daily News Double-Dose Clopidogrel Reduces Infarct Size in STEMI Patients Jason Kahn September 26, 2011
News Daily News Low US Participation in NIH-Sponsored CVD Trials Cause for Concern Jason Kahn August 01, 2011
News Industry News Abbott Receives U.S. FDA Approval for XIENCE nano™ to Treat Coronary Artery Disease in Small Vessels May 24, 2011
Video » Interview TCT 2017: Dr. C. Michael Gibson talks with Dr. Robert Harrington about advice for the next generation May 11, 2018
Video » Interview TCT 2016: Dr. C. Michael Gibson talks with Dr. Robert Harrington about Patient-Centered Outcomes Research May 11, 2018
CME A New Era of P2Y12 Inhibitors: Transitioning from Intravenous to Oral Platelet Inhibitors after PCI